Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice

BACKGROUND: Current clinical trials are using radiation therapy (RT) to enhance an antitumor response elicited by high-dose interleukin (IL)-2 therapy or immune checkpoint blockade (ICB). Bempegaldesleukin (BEMPEG) is an investigational CD122-preferential IL-2 pathway agonist with prolonged in vivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pieper, Alexander A, Rakhmilevich, Alexander L, Spiegelman, Daniel V, Patel, Ravi B, Birstler, Jen, Jin, Won Jong, Carlson, Peter M, Charych, Deborah H, Hank, Jacquelyn A, Erbe, Amy K, Overwijk, Willem W, Morris, Zachary S, Sondel, Paul M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237721/
https://www.ncbi.nlm.nih.gov/pubmed/34172518
http://dx.doi.org/10.1136/jitc-2021-002715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237721/
https://www.ncbi.nlm.nih.gov/pubmed/34172518
http://dx.doi.org/10.1136/jitc-2021-002715

Ejemplares similares